Skip to main content
Back
KBYPF logo

Kobayashi Pharmaceutical Co., Ltd.

Data quality: 100%
Overbought
KBYPF
OTC Consumer Defensive Household & Personal Products
$34.05
$0.00 (0.00%)
Mkt Cap: 2.53B
Day Range
$34.05 $34.05
52-Week Range
$34.05 $37.43
Volume
1,468
50D / 200D Avg
$34.13 / $35.66
Prev Close
$34.05

Price History

Financial Trends

Peer Comparison

vs Consumer Defensive sector median (329 peers)

Metric Stock Sector Median
P/E 0.7 10.4
P/B 0.0 1.2
ROE % 1.7 12.3
Net Margin % 2.2 5.3
Rev Growth 5Y % 1.7 5.6
D/E 0.0 0.6

Key Takeaways

Revenue grew 1.67% annually over 5 years — modest growth
Earnings declined -63.65% over the past year
ROE of 1.72% is below average
Debt/Equity of 0.00 — conservative balance sheet
Generating 12.35B in free cash flow
P/E of 0.69 — trading at a low valuation

Growth

Revenue Growth (5Y)
1.67%
Revenue (1Y)0.17%
Earnings (1Y)-63.65%
FCF Growth (3Y)60.54%

Quality

Return on Equity
1.72%
ROIC5.26%
Net Margin2.21%
Op. Margin8.96%

Safety

Debt / Equity
0.00
Current Ratio2.47
Interest Coverage530.18

Valuation

P/E Ratio
0.69
P/B Ratio0.01
EV/EBITDA-3.98
Dividend Yield0.02%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 0.17% Revenue Growth (3Y) -2.21%
Earnings Growth (1Y) -63.65% Earnings Growth (3Y) -57.58%
Revenue Growth (5Y) 1.67% Earnings Growth (5Y) -34.36%
Profitability
Revenue (TTM) 165.89B Net Income (TTM) 3.66B
ROE 1.72% ROA 1.33%
Gross Margin 47.93% Operating Margin 8.96%
Net Margin 2.21% Free Cash Flow (TTM) 12.35B
ROIC 5.26% FCF Growth (3Y) 60.54%
Safety
Debt / Equity 0.00 Current Ratio 2.47
Interest Coverage 530.18 Dividend Yield 0.02%
Valuation
P/E Ratio 0.69 P/B Ratio 0.01
P/S Ratio 0.02 PEG Ratio -1.72
EV/EBITDA -3.98 Dividend Yield 0.02%
Market Cap 2.53B Enterprise Value -59.16B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 165.89B 165.60B 173.46B 166.26B 155.25B
Net Income 3.66B 10.07B 20.34B 20.02B 19.72B
EPS (Diluted) 48.62 135.42 268.16 259.59 252.36
Gross Profit 79.51B 87.60B 96.38B 92.33B 88.77B
Operating Income 14.86B 24.86B 25.78B 26.67B 26.07B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 275.57B 265.37B 267.47B 255.83B 252.55B
Total Liabilities 64.37B 51.90B 62.66B 57.93B 56.96B
Shareholders' Equity 211.18B 213.47B 204.82B 197.90B 195.60B
Total Debt 678.59M 846.00M 987.00M 792.00M 630.00M
Cash & Equivalents 62.37B 50.87B 71.54B 96.23B 95.02B
Current Assets 148.95B 144.47B 158.33B 172.89B 181.89B
Current Liabilities 60.19B 46.42B 56.11B 51.81B 50.70B

Strategy Scores

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#576 of 819
34
Value Defensive Investing (Benjamin Graham)
#617 of 707
5

Recent Activity

Entered Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entered Defensive Investing (Benjamin Graham)
Mar 24, 2026